Abstract

Calreticulin (CALR) is a highly conserved multi-function protein that primarily localizes within the lumen of the endoplasmic reticulum (ER). It participates in various processes in the cells, including glycoprotein chaperoning, regulation of Ca2+ homeostasis, antigen processing and presentation for adaptive immune response, cell adhesion/migration, cell proliferation, immunogenic cell death, gene expression and RNA stability. The role of CALR in the assembly, retrieval and cell surface expression of MHC class I molecules is well known. A fraction of the total cellular CALR is localized in the cytosol, following its retro-translocation from the ER. In the cell stress conditions, CALR is also expressed on the cell surface via an interaction with phosphatidylserine localized on the inner leaflet of the plasma membrane. The abovementioned mechanism is relevant for the recognition of the cells, as well as immunogenicity and phagocytic uptake of proapoptotic and apoptotic cells. Lastly, the presence of CALR exon 9 gene mutations was confirmed in patients with myeloproliferative neoplasms. Their presence results in an abnormal CALR structure due to the loss of its ER-retention sequence, CALR extra-ER localisation, the formation of a complex with thrombopoietin receptor, and oncogenic transformation of hematopoietic stem cells. It is also known that CALR exon 9 mutants are highly immunogenic and induce T cell response. Despite this fact, CALR mutant positive hematopoietic cells emerge. The last phenomenon is probably the result of the inhibition of phagocytosis of the cancer cells exposing CALR mutant protein by dendritic cells.

References

• 1. Alaiya A., Roblick U., Egevad L., Carlsson A., Franzén B., VolzD., Huwendiek S., Linder S., Auer G.: Polypeptide expression inprostate hyperplasia and prostate adenocarcinoma. Anal. Cell.Pathol., 2000; 21: 1-9
  Google Scholar
• 2. Alfonso P., Núñez A., Madoz-Gurpide J., Lombardia L., SánchezL., Casal J.I.: Proteomic expression analysis of colorectal cancerby two-dimensional differential gel electrophoresis. Proteomics,2005; 5: 2602-2611 3 Araki M., Yang Y., Masubuchi N., Hironaka Y., Takei H., MorishitaS., Mizukami Y., Kan S., Shirane S., Edahiro Y., Sunami Y., Ohsaka A.,Komatsu N.: Activation of the thrombopoietin receptor by mutantcalreticulin in CALR-mutant myeloproliferative neoplasms. Blood,2016; 127: 1307-1316
  Google Scholar
• 3. opsonise bacteria for phagocytosis by microglia. Front. Immunol.,2019; 10: 2647
  Google Scholar
• 4. Arshad N., Cresswell P.: Tumor-associated calreticulin variantsfunctionally compromise the peptide loading complex and impairits recruitment of MHC-I. J. Biol. Chem., 2018; 293: 9555-9569
  Google Scholar
• 5. Chachoua I., Pecquet C., El-Khoury M., Nivarthi H., Albu R.I.,Marty C., Gryshkova V., Defour J.P., Vertenoeil G., Ngo A., Koay A.,Raslova H., Courtoy P.J., Choong M.L., Plo I., et al.: Thrombopoietinreceptor activation by myeloproliferative neoplasm associatedcalreticulin mutants. Blood, 2016; 127: 1325-1335
  Google Scholar
• 6. Chahed K., Kabbage M., Ehret-Sabatier L., Lemaitre-GuillierC., Remadi S., Hoebeke J., Chouchane L.: Expression of fibrinogenE-fragment and fibrin E-fragment is inhibited in the human infiltratingductal carcinoma of the breast: The two-dimensionalelectrophoresis and MALDI-TOF-mass spectrometry analyses. Int.J. Oncol., 2005; 27: 1425-1431
  Google Scholar
• 7. Chang H.H., Lee H., Hu M.K., Tsao P.N., Juan H.F., Huang M.C.,Shih Y.Y., Wang B.J., Jeng Y.M., Chang C.L., Huang S.F., Tsay Y.G.,Hsieh F.J., Lin K.H., Hsu W.M., et al.: Notch1 expression predicts anunfavorable prognosis and serves as a therapeutic target of patientswith neuroblastoma. Clin. Cancer Res., 2010; 16: 4411-4420
  Google Scholar
• 8. Chao M.P., Jaiswal S., Weissman-Tsukamoto R., Alizadeh A.A.,Gentles A.J., Volkmer J., Weiskopf K., Willingham S.B., Raveh T.,Park C.Y., Majeti R., Weissman I.L.: Calreticulin is the dominantpro-phagocytic signal on multiple human cancers and is counterbalancedby CD47. Sci. Transl. Med., 2010; 2: 63ra94
  Google Scholar
• 9. Chiang W.F., Hwang T.Z., Hour T.C., Wang L.H., Chiu C.C., ChenH.R., Wu Y.J., Wang C.C., Wang L.F., Chien C.Y., Chen J.H., Hsu C.T.,Chen J.Y.F.: Calreticulin, an endoplasmic reticulum-resident protein,is highly expressed and essential for cell proliferation andmigration in oral squamous cell carcinoma. Oral Oncol., 2013; 49:534-541
  Google Scholar
• 10. Cid N.D., Jeffery E., Rizvi S.M., Stamper E., Peters L.R., Brown W.C.,Provoda C., Raghavan M.: Modes of calreticulin recruitment to themajor histocompatibility complex class I assembly pathway. J. Biol.Chem., 2010; 285: 4520-4535
  Google Scholar
• 11. Cockram T.O.J., Puigdellívol M., Brown G.C.: Calreticulin and galectin-
  Google Scholar
• 12. Coppolino M.G., Woodside M.J., Demaurex N., Grinstein S., St-Arnaud R., Dedhar S.: Calreticulin is essential for integrin-mediatedcalcium signalling and cell adhesion. Nature, 1997; 386: 843-847
  Google Scholar
• 13. Cordua S., Kjaer L., Skov V., Pallisgaard N., Hasselbalch H.C., EllervikC.: Prevalence and phenotypes of JAK2 V617F and calreticulinmutations in a Danish general population. Blood, 2019; 134: 469-479
  Google Scholar
• 14. Di Martino S., Crescente G., De Lucia V., Di Paolo M., Marotta G.,De Lucia D., Abbadessa A.: The emerging role of calreticulin in cancercells. World Cancer Res. J., 2017; 4: e926
  Google Scholar
• 15. Du X.L., Hu H., Lin D.C., Xia S.H., Shen X.M., Zhang Y., Luo M.L.,Feng Y.B., Cai Y., Xu X., Han Y.L., Zhan Q.M., Wang M.R.: Proteomicprofiling of proteins dysregulated in Chinese esophageal squamouscell carcinoma. J. Mol. Med., 2007; 85: 863-875
  Google Scholar
• 16. Eder-Azanza L., Navarro D., Aranaz P., Novo F.J., Cross N.C., VizmanosJ.L.: Bioinformatic analyses of CALR mutations in myeloproliferativeneoplasms support a role in signaling. Leukemia, 2014; 28:2106-2109
  Google Scholar
• 17. Eggleton P., Bremer E., Dudek E., Michalak M.: Calreticulin, a therapeutictarget? Expert Opin. Ther. Targets, 2016; 20: 1137-1147
  Google Scholar
• 18. Elf S., Abdelfattah N.S., Chen E., Perales-Patón J., Rosen E.A., Ko A.,Peisker F., Florescu N., Giannini S., Wolach O., Morgan E.A., Tothova Z.,Losman J.A., Schneider R.K., Al-Shahrour F., et al.: Mutant calreticulinrequires both its mutant C-terminus and the thrombopoietin receptorfor oncogenic transformation. Cancer Discov., 2016; 6: 368-381
  Google Scholar
• 19. Falchi M., Varricchio L., Martelli F., Marra M., Picconi O., Tafuri A.,Girelli G., Uversky V.N., Migliaccio A.R.: The calreticulin control of humanstress erythropoiesis is impaired by JAK2V617F in polycythemiavera. Exp. Hematol., 2017; 50: 53-76
  Google Scholar
• 20. Fucikova J., Becht E., Iribarren K., Goc J., Remark R., DamotteD., Alifano M., Devi P., Biton J., Germain C., Lupo A., Fridman W.H.,Dieu-Nosjean M.C., Kroemer G., Sautès-Fridman C., et al.: Calreticulinexpression in human non-small cell lung cancers correlates withincreased accumulation of antitumor immune cells and favorableprognosis. Cancer Res., 2016; 76: 1746-1756
  Google Scholar
• 21. Fucikova J., Kline J.P., Galluzzi L., Spisek R.: Calreticulin arms NKcells against leukemia. Oncoimmunology, 2020; 9: 1671763
  Google Scholar
• 22. Fucikova J., Moserova I., Urbanova L., Bezu L., Kepp O., Cremer I.,Salek C., Strnad P., Kroemer G., Galluzzi L., Spisek R.: Prognostic andpredictive value of DAMPs and DAMP-associated processes in cancer.Front. Immunol., 2015; 6: 402
  Google Scholar
• 23. Fucikova J., Truxova I., Hensler M., Becht E., Kasikova L., MoserovaI., Vosahlikova S., Klouckova J., Church S.E., Cremer I., Kepp O.,Kroemer G., Galluzzi L., Salek C., Spisek R.: Calreticulin exposure bymalignant blasts correlates with robust anticancer immunity and improvedclinical outcome in AML patients. Blood, 2016; 128: 3113-3124
  Google Scholar
• 24. Galluzzi L., Buqué A., Kepp O., Zitvogel L., Kroemer G.: Immunogeniccell death in cancer and infectious disease. Nat. Rev. Immunol.,2017; 17: 97-111
  Google Scholar
• 25. Guo L., Nakamura K., Lynch J., Opas M., Olson E.N., Agellon L.B.,Michalak M.: Cardiac-specific expression of calcineurin reverses embryoniclethality in calreticulin-deficient mouse. J. Biol. Chem., 2002;277: 50776-50779
  Google Scholar
• 26. Han A., Li C., Zahed T., Wong M., Smith I., Hoedel K., Green D.,Boiko A.D.: Calreticulin is a critical cell survival factor in malignantneoplasms. PLoS Biol., 2019; 17: e3000402
  Google Scholar
• 27. Han L., Schubert C., Köhler J., Schemionek M., Isfort S., BrümmendorfT.H., Koschmieder S., Chatain N.: Calreticulin-mutant proteinsinduce megakaryocytic signaling to transform hematopoieticcells and undergo accelerated degradation and Golgi-mediated secretion.J. Hematol. Oncol., 2016; 9: 45
  Google Scholar
• 28. Hellman K., Alaiya A.A., Schedvins K., Steinberg W., HellströmA.C., Auer G.: Protein expression patterns in primary carcinoma ofthe vagina. Br. J. Cancer, 2004; 91: 319-326
  Google Scholar
• 29. Holmström M.O., Cordua S., Skov V., Kjær L., Pallisgaard N., EllervikC., Hasselbalch H.C., Andersen M.H.: Evidence of immune elimination,immuno-editing and immune escape in patients with hematologicalcancer. Cancer Immunol. Immunother., 2020; 69: 315-324
  Google Scholar
• 30. Holmström M.O., Martinenaite E., Ahmad S.M., Met Ö., FrieseC., Kjær L., Riley C.H., Thor Straten P., Svane I.M., Hasselbalch H.C.,Andersen M.H.: The calreticulin (CALR) exon 9 mutations are promisingtargets for cancer immune therapy. Leukemia, 2018; 32: 429-437
  Google Scholar
• 31. How J., Hobbs G.S., Mullally A.: Mutant calreticulin in myeloproliferativeneoplasms. Blood, 2019; 134: 2242-2248
  Google Scholar
• 32. Hsu W.M., Hsieh F.J., Jeng Y.M., Kuo M.L., Chen C.N., Lai D.M.,Hsieh L.J., Wang B.T., Tsao P.N., Lee H., Lin M.T., Lai H.S., Chen W.J.:Calreticulin expression in neuroblastoma – a novel independentprognostic factor. Ann. Oncol., 2005; 16: 314-321
  Google Scholar
• 33. Jo S.H., Choi J.A., Lim Y.J., Lee J., Cho S.N., Oh S.M., Go D., KimS.H., Song C.H.: Calreticulin modulates the intracellular survival ofmycobacteria by regulating ER-stress-mediated apoptosis. Oncotarget,2017; 8: 58686-58698
  Google Scholar
• 34. Kageyama S., Isono T., Matsuda S., Ushio Y., Satomura S., TeraiA., Arai Y., Kawakita M., Okada Y., Yoshiki T.: Urinary calreticulinin the diagnosis of bladder urothelial carcinoma. Int. J. Urol., 2009;16: 481-486
  Google Scholar
• 35. Kasikova L., Hensler M., Truxova I., Skapa P., Laco J., Belicova L.,Praznovec I., Vosahlikova S., Halaska M.J., Brtnicky T., Rob L., Presl J.,Kostun J., Cremer I., Ryska A., et al.: Calreticulin exposure correlateswith robust adaptive antitumor immunity and favorable prognosisin ovarian carcinoma patients. J. Immunother. Cancer, 2019; 7: 312
  Google Scholar
• 36. Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., RumiE., Milosevic J.D., Them N.C., Berg T., Gisslinger B., Pietra D., ChenD., Vladimer G.I., Bagienski K., Milanesi C., Casetti I.C., et al.: Somaticmutations of calreticulin in myeloproliferative neoplasms. N. Engl.J. Med., 2013; 369: 2379-2390
  Google Scholar
• 37. Limjindaporn T., Wongwiwat W., Noisakran S., Srisawat C., NetsawangJ., Puttikhunt C., Kasinrerk W., Avirutnan P., Thiemmeca S.,Sriburi R., Sittisombut N., Malasit P., Yenchitsomanus P.: Interactionof dengue virus envelope protein with endoplasmic reticulumresidentchaperones facilitates dengue virus production. Biochem.Biophys. Res. Commun., 2009; 379: 196-200
  Google Scholar
• 38. Liu P., Zhao L., Kroemer G., Kepp O.: Secreted calreticulin mutantssubvert anticancer immunosurveillance. OncoImmunology,2019; 9: 1708126
  Google Scholar
• 39. Liu P., Zhao L., Loos F., Marty C., Xie W., Martins I., Lachkar S.,Qu B., Waeckel-Énée E., Plo I., Vainchenker W., Perez F., RodriguezD., López-Otin C., van Endert P., et al.: Immunosuppression by mutatedcalreticulin released from malignant cells. Mol. Cell, 2020;77: 748-760.e9
  Google Scholar
• 40. Lu Y.C., Weng W.C., Lee H.: Functional roles of calreticulin incancer biology. Biomed. Res. Int., 2015; 2015: 526524
  Google Scholar
• 41. Lwin Z.M., Guo C., Salim A., Yip G.W., Chew F.T., Nan J., Thike A.A.,Tan P.H., Bay B.H.: Clinicopathological significance of calreticulin inbreast invasive ductal carcinoma. Mod. Pathol., 2010; 23: 1559-1566
  Google Scholar
• 42. Lynch J., Guo L., Gelebart P., Chilibeck K., Xu J., Molkentin J.D.,Agellon L.B., Michalak M.: Calreticulin signals upstream of calcineurinand MEF2C in a critical Ca2+-dependent signaling cascade.J. Cell Biol., 2005; 170: 37-47
  Google Scholar
• 43. Margolin E., Oh Y.J., Verbeek M., Naude J., Ponndorf D., MeshcheriakovaY.A., Peyret H., van Diepen M.T., Chapman R., MeyersA.E., Lomonossoff G.P., Matoba N., Williamson A.L., Rybicki E.P.:Co-expression of human calreticulin significantly improves theproduction of HIV gp140 and other viral glycoproteins in plants.Plant Biotechnol. J., 2020; 18: 2109-2117
  Google Scholar
• 44. Marty C., Pecquet C., Nivarthi H., El-Khoury M., Chachoua I.,Tulliez M., Villeval J.L., Raslova H., Kralovics R., ConstantinescuS.N., Plo I., Vainchenker W.: Calreticulin mutants in mice inducean MPL-dependent thrombocytosis with frequent progression tomyelofibrosis. Blood, 2016; 127: 1317-1324
  Google Scholar
• 45. Mesaeli N., Nakamura K., Zvaritch E., Dickie P., Dziak E., KrauseK.H., Opas M., MacLennan D.H., Michalak M.: Calreticulin is essentialfor cardiac development. J. Cell Biol., 1999; 144: 857-868
  Google Scholar
• 46. Michalak M., Groenendyk J., Szabo E., Gold L.I., Opas M.: Calreticulin,a multi-process calcium-buffering chaperone of the endoplasmicreticulum. Biochem. J., 2009; 417: 651-666
  Google Scholar
• 47. Migliaccio A.R., Uversky V.N.: Dissecting physical structureof calreticulin, an intrinsically disordered Ca2+-buffering chaperonefrom endoplasmic reticulum. J. Biomol. Struct. Dyn., 2018;36: 1617-1636
  Google Scholar
• 48. Nakamura K., Zuppini A., Arnaudeau S., Lynch J., Ahsan I.,Krause R., Papp S., De Smedt H., Parys J.B., Muller-Esterl W., LewD.P., Krause K.H., Demaurex N., Opas M., Michalak M.: Functionalspecialization of calreticulin domains. J. Cell Biol., 2001; 154: 961-972
  Google Scholar
• 49. Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., WedgeD.C., Avezov E., Li J., Kollmann K., Kent D.G., Aziz A., Godfrey A.L.,Hinton J., Martincorena I., Van Loo P., et al.: Somatic CALR mutationsin myeloproliferative neoplasms with nonmutated JAK2. N.Engl. J. Med., 2013; 369: 2391-2405
  Google Scholar
• 50. Nguyen T.O., Capra J.D., Sontheimer R.D.: Calreticulin is transcriptionallyupregulated by heat shock, calcium and heavy metals.Mol. Immunol., 1996; 33: 379-386
  Google Scholar
• 51. Ostwald T.J., MacLennan D.H.: Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum. J. Biol. Chem.,1974; 249: 974-979
  Google Scholar
• 52. Païdassi H., Tacnet-Delorme P., Verneret M., Gaboriaud C.,Houen G., Duus K., Ling W.L., Arlaud G.J., Frachet P.: Investigationson the C1q-calreticulin-phosphatidylserine interactions yieldnew insights into apoptotic cell recognition. J. Mol. Biol., 2011;408: 277-290
  Google Scholar
• 53. Papp S., Fadel M.P., Kim H., McCulloch C.A., Opas M.: Calreticulinaffects fibronectin-based cell-substratum adhesion via theregulation of c-Src activity. J. Biol. Chem., 2007; 282: 16585-16598
  Google Scholar
• 54. Park S., Huh H.J., Mun Y.C., Seong C.M., Chung W.S., ChungH.S., Huh J.: Calreticulin mRNA expression and clinicopathologicalcharacteristics in acute myeloid leukemia. Cancer Genet., 2015;208: 630-635
  Google Scholar
• 55. Peng R.Q., Chen Y.B., Ding Y., Zhang R., Zhang X., Yu X.J., ZhouZ.W., Zeng Y.X., Zhang X.S.: Expression of calreticulin is associatedwith infiltration of T-cells in stage IIIB colon cancer. World J. Gastroenterol.,2010; 16: 2428-2434
  Google Scholar
• 56. Pietra D., Rumi E., Ferretti V.V., Di Buduo C.A., Milanesi C.,Cavalloni C., Sant’Antonio E., Abbonante V., Moccia F., Casetti I.C.,Bellini M., Renna M.C., Roncoroni E., Fugazza E., Astori C., et al.:Differential clinical effects of different mutation subtypes in CALRmutantmyeloproliferative neoplasms. Leukemia, 2016; 30: 431-438
  Google Scholar
• 57. Qiu Y., Lynch J., Guo L., Yatsula B., Perkins A.S., Michalak M.:Regulation of the calreticulin gene by GATA6 and Evi-1 transcriptionfactors. Biochemistry, 2008; 47: 3697-3704
  Google Scholar
• 58. Saito Y., Ihara Y., Leach M.R., Cohen-Doyle M.F., Williams D.B.:Calreticulin functions in vitro as a molecular chaperone for both glycosylated and non-glycosylated proteins. EMBO J., 1999; 18:6718-6729
  Google Scholar
• 59. Schcolnik-Cabrera A., Oldak B., Juárez M., Cruz-Rivera M.,Flisser A., Mendlovic F.: Calreticulin in phagocytosis and cancer:Opposite roles in immune response outcomes. Apoptosis, 2019;24: 245-255
  Google Scholar
• 60. Sheng W., Chen C., Dong M., Zhou J., Liu Q., Dong Q., Li F.: Overexpressionof calreticulin contributes to the development and progressionof pancreatic cancer. J. Cell. Physiol., 2014; 229: 887-897
  Google Scholar
• 61. Shide K., Kameda T., Yamaji T., Sekine M., Inada N., KamiuntenA., Akizuki K., Nakamura K., Hidaka T., Kubuki Y., Shimoda H., KitanakaA., Honda A., Sawaguchi A., Abe H., et al.: Calreticulin mutantmice develop essential thrombocythemia that is amelioratedby the JAK inhibitor ruxolitinib. Leukemia, 2017; 31: 1136-1144
  Google Scholar
• 62. Shivarov V., Ivanova M., Tiu R.V.: Mutated calreticulin retainsstructurally disordered C terminus that cannot bind Ca2+: Somemechanistic and therapeutic implications. Blood Cancer J., 2014;4: e185
  Google Scholar
• 63. Stanley R.F., Steidl U.: Molecular mechanism of mutant CALRmediatedtransformation. Cancer Discov., 2016; 6: 344-346
  Google Scholar
• 64. Szuber N., Lamontagne B., Busque L.: Novel germline mutationsin the calreticulin gene: Implications for the diagnosis ofmyeloproliferative neoplasms. J. Clin. Pathol., 2016; 69: 1033-1036
  Google Scholar
• 65. Tefferi A., Wassie E.A., Guglielmelli P., Gangat N., BelachewA.A., Lasho T.L., Finke C., Ketterling R.P., Hanson C.A., PardananiA., Wolanskyj A.P., Maffioli M., Casalone R., Pacilli A., VannucchiA.M., et al.: Type 1 versus Type 2 calreticulin mutations in essentialthrombocythemia: A collaborative study of 1027 patients. Am.J. Hematol., 2014; 89: E121-E124
  Google Scholar
• 66. Truxova I., Kasikova L., Salek C., Hensler M., Lysak D., HolicekP., Bilkova P., Holubova M., Chen X., Mikyskova R., Reinis M., KovarM., Tomalova B., Kline J.P., Galluzzi L., et al.: Calreticulin exposureon malignant blasts correlates with improved natural killer cellmediatedcytotoxicity in acute myeloid leukemia patients. Haematologica,2020; 105: 1868-1878
  Google Scholar
• 67. Vainchenker W., Kralovics R.: Genetic basis and molecularpathophysiology of classical myeloproliferative neoplasms. Blood,2017; 129: 667-679
  Google Scholar
• 68. Vaksman O., Davidson B., Tropé C., Reich R.: Calreticulin expressionis reduced in high-grade ovarian serous carcinoma effusionscompared with primary tumors and solid metastases. Hum.Pathol., 2013; 44: 2677-2683
  Google Scholar
• 69. Varricchio L., Falchi M., Dall’Ora M., De Benedittis C., RuggeriA., Uversky V.N., Migliaccio A.R.: Calreticulin: Challenges posed bythe intrinsically disordered nature of calreticulin to the study ofits function. Front. Cell Dev. Biol., 2017; 5: 96
  Google Scholar
• 70. Wijeyesakere S.J., Bedi S.K., Huynh D., Raghavan M.: The Cterminalacidic region of calreticulin mediates phosphatidylserinebinding and apoptotic cell phagocytosis. J. Immunol., 2016;196: 3896-3909
  Google Scholar
• 71. Wijeyesakere S.J., Gagnon J.K., Arora K., Brooks C.L.3rd, RaghavanM.: Regulation of calreticulin-major histocompatibilitycomplex (MHC) class I interactions by ATP. Proc. Natl. Acad. Sci.USA, 2015; 112: E5608-E5617
  Google Scholar
• 72. Yue X., Wang H., Zhao F., Liu S., Wu J., Ren W., Zhu Y.: HepatitisB virus-induced calreticulin protein is involved in IFN resistance.J. Immunol., 2012; 189: 279-286
  Google Scholar
• 73. Zamanian M., Veerakumarasivam A., Abdullah S., Rosli R.: Calreticulinand cancer. Pathol. Oncol. Res., 2013; 19: 149-154
  Google Scholar

Full text